HUMACYTE INC
HUMA · NASDAQ
更新於 2026-10-13 15:06:24
- 今日最高
- $0.39
- 今日最低
- $0.36
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
K線圖趨勢，實際資料以交易頁為準
關鍵數據
- 昨天開盤價
- $0.40
- 昨天收盤價
- $0.38
- 成交量
- 16.34M
- 市值
- $108.23M
- 市盈率（P/E）
- --
- 每股收益（EPS）
- $-0.48
昨天價格區間
52週價格區間
公司概況
- 板塊
- HEALTHCARE
- 行業
- Biotechnology
- 子行業
- BIOTECHNOLOGY
- 總部
- 2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM, NC, UNITED STATES, 27713
- 國家
- US
- 上市日期
- 2020-09-22
- 財年截止
- December
- 流通股數
- 269.64M
- CIK
- 0001818382
- 官方網址
- humacyte.com
Humacyte Inc (HUMA) is a groundbreaking biotechnology firm at the forefront of vascular and regenerative medicine, specializing in the development of human acellular vessels (HAVs). These innovative, off-the-shelf products are designed to meet pressing needs in vascular reconstruction and chronic disease management, improving patient outcomes and potentially reducing healthcare expenses. Leveraging its advanced technology platform, Humacyte is strategically positioned to drive innovation in transplantation and tissue engineering, thereby cementing its status as a transformative leader within the rapidly evolving landscape of medical therapies.
財務指標
營業收入
2026-06-30
$406K
2026-03-31
$495K
2025-12-31
$467K
2025-09-30
$753K
營業支出
2026-06-30
$26.17M
2026-03-31
$27.39M
2025-12-31
$20.43M
2025-09-30
$23.01M
淨利潤
2026-06-30
-$36.8M
2026-03-31
-$17.61M
2025-12-31
-$24.8M
2025-09-30
-$17.51M
淨利潤率
2026-06-30
-9.06K%
2026-03-31
-3.55K%
2025-12-31
-5.31K%
2025-09-30
-2.32K%
每股收益
2026-06-30
$-0.16
2026-03-31
$-0.09
2025-12-31
$-0.18
2025-09-30
$-0.11
息稅折舊攤銷前利潤
2026-06-30
-$32.69M
2026-03-31
-$13.55M
2025-12-31
-$19.92M
2025-09-30
-$13.03M
有效稅率
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| 項目 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| 營業收入 | $406K | $495K | $467K | $753K |
| 營業支出 | $26.17M | $27.39M | $20.43M | $23.01M |
| 淨利潤 | -$36.8M | -$17.61M | -$24.8M | -$17.51M |
| 淨利潤率 | -9.06K% | -3.55K% | -5.31K% | -2.32K% |
| 每股收益 | $-0.16 | $-0.09 | $-0.18 | $-0.11 |
| 息稅折舊攤銷前利潤 | -$32.69M | -$13.55M | -$19.92M | -$13.03M |
| 有效稅率 | -- | -- | -- | -- |
常見問題
風險提示
股價可能大幅波動，短時間內可能出現顯著漲跌。 數位資產與衍生性商品交易可能涉及槓桿、流動性等額外風險。 本頁內容僅供參考，不構成任何投資建議。 產品可用性與訪問可能因地區及適用法規而異。